Mr. Ambra is an experienced industry executive and has led various multinational drug and device development programs, many of which resulted in successful regulatory approvals. In 2012, he founded and led a full-service U.S. based CRO, DZS Clinical Services, focused on supporting small and mid-sized drug and device companies. During his time there, he led the organization through significant growth and was instrumental in developing one of the first unified eClinical platforms in the industry. In 2018, DZS was successfully acquired by the WDB Holdings group. Before that, Mr. Ambra spent 20 years in the clinical research industry, having held strategic leadership positions with leading Sponsors and CRO companies. Throughout his career, Mr. Ambra has continued to foster a culture of excellence, a sense of urgency, and a sincere desire to bring new and innovative therapeutics to patients.